Lastly, our data highlight the importance of further evaluating HRD genes and addressing PARPi resistance mechanisms, beyond BRCA1/2, in clinical settings to expand the scope of therapeutic approaches with PARPi or combination therapies to refine treatment selection for optimal personalized therapy in cancer patients. Here, BRCA1 is linked to cancer.